Bushu Pharmaceuticals Ltd. | April 28, 2021
Bushu Pharmaceuticals Ltd. has entered into a business partnership arrangement with Suzuken Co., Ltd. to provide specialty pharmaceutical producers looking to enter the Japanese market with extensive support for new product releases.
In recent years, the market has seen an increase in the number of innovative specialty pharmaceuticals, such as biopharmaceuticals, regenerative medicines, and orphan drugs for rare diseases, that require strict temperature, inventory, and security control. In line with this trend, the number of pharmaceutical companies planning to bring these types of drugs to Japan has grown. These pharmaceutical manufacturers, on the other hand, often lack the necessary infrastructure, such as production facilities, delivery centers, and networks, to reach the Japanese market with minimal resources, and must therefore outsource these functions to trusted partners.
Suzuken, Bushu Pharma's partner, has played an industry-leading role in Japan's pharmaceutical distribution market. Suzuken, one of the leading organizations in the industry, has a distribution network in Japan capable of supporting the international shipping of specialty pharmaceuticals. Bushu Pharma, on the other hand, has been in the contract manufacturing industry in Japan for over 20 years, holds GMP certifications from all over the world, and has a track record of exporting to over 43 countries. Bushu Pharma will establish a platform that provides one-stop holistic assistance for pharmaceutical producers seeking to penetrate the Japanese market by aligning functions and capabilities with Suzuken.
About Bushu Pharmaceuticals Ltd.
Bushu Pharma manufactures solid reparations, solid preparation primary packaging, injection manufacturing, and injection packaging not just for domestic pharmaceuticals but also for multinational pharmaceutical manufacturers, drawing on its expertise and understanding as a contract development and manufacturing organization (CDMO) cultivated over 20 years. Bushu Pharma has a diverse product and service offering, ranging from clinical trial supplies to commercial product development support to commercialization, as well as various production facilities and technologies.
Bushu Pharma is a leading domestic contract manufacturing company in Japan that can offer optimum solutions such as technology transfer, production, packaging, and logistics from project start to project approval.
Moderna | December 16, 2020
It would appear that Pfizer and BioNTech's COVID-19 immunization was not the sole objective of a new cyberattack at the European Medicines Agency.
Moderna said Monday that reports from its pre-accommodation conversations with EMA about its shot, mRNA-1273, were "unlawfully gotten to" by programmers, refering to a warning from the organization.
The assailants didn't get individual data about preliminary members, Moderna said. The organization's EMA accommodation did exclude any information recognizing people in the examination.
Now, no extra insights concerning the cyberattack, for example, the size of the penetrate or the character of any suspects—are accessible, and Moderna said it anticipates results from EMA's progressing examination.
The disclosure came days after the EMA initially uncovered the cyberattack, and Pfizer and BioNTech's COVID-19 immunization applicant, BNT162b2, was the principal distinguished as an objective.
EMA choices on the two immunizations are moving close. Medication commentators at the EMA's Committee for Medicinal Products for Human Use are booked to evaluate BNT162b2 on Dec. 29 and mRNA-1273 on Jan. 12.
Moderna was recently focused by programmers looking for its COVID-19 examination, in a cyberattack supposedly upheld by the Chinese government.
The U.S. Branch of Justice in July arraigned two Chinese nationals for running a 10-year hacking effort that most as of late rotated to focusing on organizations doing COVID research. Reuters later affirmed Moderna as the antibody producer referenced in the arraignment. China has denied any function in such practices.
Other than Moderna and Pfizer/BioNTech, rival COVID immunization designers AstraZeneca, Johnson and Johnson and Novavax apparently have arrived in the line of sight of North Korean programmers. In those hacking endeavors, the assailants regularly conveyed noxious reports or connections by means of email under the appearance of occupation enrollment specialists, partners or different associates of the person in question, as indicated by individuals acquainted with the issue refered to by The Wall Street Journal.
Country state programmers from Iran and Russia have likewise been blamed for attempting to take COVID-related data.
MEDISCA | June 18, 2021
MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee.
MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company with 32 years of experience. The company's top priority is to automate processes throughout its sales, service, and marketing divisions and replace at least five disparate systems.
"We picked Creatio because of its unified low-code/no-code platform for process management and CRM, which will help us with our business and marketing demands," said Ekaterina Dobrokhotova, Director of Global Marketing. "We can manage the automation of our business processes with Creatio's low-code/no-code tools, giving us more control and flexibility over our operations. It also enables us to put more resources to more complicated, strategic tasks."
Creatio aims to assist companies in accelerating by providing solutions to quickly and easily automate business ideas. Creatio provides a modular approach to app development and process automation to help speed up processes even more. The out-of-the-box capacity of Creatio eliminates the need to build core modules for apps from scratch. Instead, its pre-configured modules provide similar basic functionalities required for several apps and can be useful to achieve new solutions more quickly.
Solutions Metrix is in charge of the system's implementation.
"In the increasingly competitive and rapidly evolving Pharmaceutical compounding market, we are excited to partner with MEDISCA to help them accelerate their growth and achieve strategic business objectives through the power of Creatio's industry-leading low-code/no-code platform," said Thomas James Stewart, Executive Vice-President & Managing Partner.
About Solutions Metrix
Since 2001, Solutions Metrix has been implementing globally known CRM platforms such as Creatio for the North American market across various industries and businesses of all sizes.
CRM consulting services from Solution Metrix focus on accelerating growth and accomplishing strategic business objectives for its partners/clients. Their team of seasoned Business & CRM Consultants will guarantee that every implementation is best practices focused and adapted to your company's specific business processes and needs, using a unique consultative approach & methodology that is ROI & user-adoption driven to assure success.
MEDISCA is the global leader in turnkey solutions for the pharmaceutical compounding industry and associated health care professionals. MEDISCA is committed to being a one-stop-shop for prescribers, pharmacists, and pharmacy technicians involved in personalized medicine by providing high-quality products, cutting-edge technology, industry-leading compounded support, and education through its partnership with LP3 Network. Founded in 1989, the company now has offices in Canada, the United States, and Australia, allowing it to serve the international market better.